Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRASPA versus reference L-asparaginase with standard polychemotherapy in first relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia
2009-012584-34Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Oct 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eryaspase in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by PHAXIAM Therapeutics. Started Oct 2009; status: completed.
02
Drugs
eryaspase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-012584-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012584-34.